摘要:
The invention relates to pharmaceutical preparations comprising at least one emulsifier, at least one emulsifier adjunct and/or solvent and at least one lipid, characterised in that the mass ratio of emulsifier to emulsifier adjunct and/or solvent (Smix) is 1:1 to 9:1 and the total lipid fraction is > 0 % (m/m). Said preparation at least partly inhibits at least one intestinal enzyme and/or at least one intestinal efflux system. Said preparations may be used to increase the bioavailability of medicaments which are lipophilic and/or substrates for intestinal metabolising enzymes and/or intestinal efflux systems, in particular steroids.
摘要:
The invention relates to 17α-alkyl-17β-oxy-estra-1,3,5(10)-trienes having an anti-oestrogen action, of general formula (I). The invention also relates to 17-oxo-estra-1,3,5(10)-trienes and 17β-hydroxy-estra-1,3,5(10)-trienes as intermediates for producing the inventive estratrienes. The invention further relates to the use of 17α-alkyl-17β-oxy-estratrienes for the production of medicaments and pharmaceutical preparations containing at least one 17α-alkyl-17β-oxy-estratriene and at least one pharmaceutically acceptable carrier.
摘要:
The invention relates to substituted antiadrogenic pyrrolidines N-[φ-[3-[4-cyan-3-(trifluoromethyl)-phenyl]-5.5-dimethyl-4-oxo2-thioxoimidazoline-1-yle]alkyl] of formula (I) having a salient antiproliferative effect profile. Said invention also relates to a method for producing compounds of the formula (I), pharmaceutical preparations and to the use thereof for producing drugs.